Literature DB >> 15257864

Compelling drug indications in diabetic and nondiabetic nephropathy.

Eberhard Ritz1, Ralf Dikow, Martin Zeier.   

Abstract

To halt progression of renal disease, the combination of several interventional strategies is recommended. The most important components comprise lowering of systolic blood pressure to approximately 120 mm Hg; providing pharmacologic blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; and reducing proteinuria to rates of less than 1 g/d.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15257864     DOI： 10.1007/s11906-004-0024-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


  87 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

4.  Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats.

Authors:  Akira Nishiyama; Dale M Seth; L Gabriel Navar
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

5.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

7.  Insulin resistance and risk of chronic kidney disease in nondiabetic US adults.

Authors:  Jing Chen; Paul Muntner; L Lee Hamm; Vivian Fonseca; Vecihi Batuman; Paul K Whelton; Jiang He
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

8.  Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group.

Authors:  M M Schwartz; E J Lewis; T Leonard-Martin; J B Lewis; D Batlle
Journal:  Nephrol Dial Transplant       Date:  1998-10       Impact factor: 5.992

9.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.

Authors:  M Ravid; R Lang; R Rachmani; M Lishner
Journal:  Arch Intern Med       Date:  1996-02-12

Review 10.  Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.

Authors:  Niels H Andersen; Søren T Knudsen; Per L Poulsen; Steen H Poulsen; Kjeld Helleberg; Hans Eiskjaer; Klaus W Hansen; Toke Bek; Carl E Mogensen
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2003-06       Impact factor: 1.636
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.